Boston Scientific Corporation

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Boston Scientific Corporation sits in the top decile of US sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count).

280 total trials 22 currently recruiting 207 completed later-stage tilt top decile by trial count

Boston Scientific Corporation: 280 sponsored US clinical trials, 22 recruiting.

Boston Scientific Corporation sponsors 280 registered US clinical trials on ClinicalTrials.gov, 22 of them currently recruiting, and 207 completed. 59 of these trials are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Coronary Artery Disease, with 8 trials.

Top-decile sponsor footprint

Boston Scientific Corporation ranks in the top decile of sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

207 of 239 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

280 total, page 5 of 6

COMPLETED Phase 3

PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)

NCT01510327

COMPLETED NA

Multicenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy

NCT00947310

TERMINATED

Longitudinal Surveillance Registry (LSR) of ACUITY Spiral

NCT00955708

COMPLETED Phase 2

An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins

NCT00928421

COMPLETED Phase 3

EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries

NCT00896337

COMPLETED Phase 4

Optimized Programming in Spinal Cord Stimulation (SCS) System

NCT00871819

COMPLETED NA

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels

NCT01498692

COMPLETED Phase 3

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)

NCT01500434

COMPLETED Phase 3

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions

NCT00823212

COMPLETED

Evaluation of Left Ventricular AutoThreshold

NCT00812201

COMPLETED Phase 4

A Carotid Stenting Boston Scientific Surveillance Program

NCT00741091

TERMINATED NA

APPROPRIATE - Rate Adaptive Pacing Sensor

NCT00757666

TERMINATED

Correlation Of Respiratory Rate Level And Trend Evaluation in Heart Failure Patients

NCT00758121

COMPLETED Phase 2

Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence

NCT00758420

TERMINATED NA

Restoration of Chronotropic Competence in Heart Failure Patients With Normal Ejection Fraction

NCT00670111

COMPLETED NA

Investigating Superion™ In Spinal Stenosis

NCT00692276

COMPLETED Phase 4

Comparison of AV Optimization Methods Used in Cardiac Resynchronization Therapy (CRT)

NCT00677014

TERMINATED Phase 2

Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

NCT00573131

COMPLETED Phase 2

A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation

NCT00528021

COMPLETED Phase 3

TAXUS PERSEUS Workhorse

NCT00484315

COMPLETED Phase 3

TAXUS PERSEUS Small Vessel

NCT00489541

TERMINATED Phase 4

Post-Approval Study of the NexStent Carotid Stent System and the FilterWire EZ Embolic Protection System: SONOMA

NCT00478673

COMPLETED Phase 3

A Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction

NCT00433771

COMPLETED Phase 2

Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt

NCT00442364

TERMINATED Phase 1

A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma

NCT00479765

TERMINATED Phase 4

Spinal Cord Stimulation for Painful Diabetic Neuropathy

NCT00487981

COMPLETED NA

Changes in Cerebral Blood Flow in Patients Treated With Spinal Cord Stimulation for Low Back and Leg Pain

NCT00418301

COMPLETED Phase 2

TheraSphere for the Treatment of Liver Metastases

NCT00511862

COMPLETED

The Prefyx PPS™ System eRegistry

NCT00688181

COMPLETED

Spy II Clinical Registry

NCT00751998

COMPLETED Phase 4

Effect of Pulse Width With Spinal Cord Stimulation

NCT00399516

TERMINATED NA

Spinal Cord Stimulation (SCS) for Neuropathic Pain of Back or Lower Extremity

NCT00399841

TERMINATED NA

Effectiveness of Precision Spinal Cord Stimulation With Artisan Paddle Electrode

NCT00386724

TERMINATED NA

Efficacy of the Spinal Cord Stimulation System as Salvage Therapy

NCT00387244

COMPLETED NA

TC-WYRE: TAXUS Express Stent vs. Cypher Stent - What's Your Real Life Experience?

NCT00344630

COMPLETED

RAPID-RF: Remote Active Monitoring in Patients With Heart Failure

NCT00334451

COMPLETED NA

REASSURE AV Registry

NCT01074034

COMPLETED Phase 2

EASYTRAK 3 Downsize Lead

NCT00384722

COMPLETED NA

Treatment for Migraines With an Implantable Device

NCT00286078

TERMINATED NA

Spinal Cord Stimulation for Chronic and Intractable Back Pain

NCT00370695

COMPLETED Phase 4

A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)

NCT00628901

TERMINATED Phase 4

Comparison of Intraspinal Nerve Root Stimulation With Dorsal Column Stimulation

NCT00370773

COMPLETED

First Arrhythmia Collection of Transvenous and Simultaneous Subcutaneous Implantable Defibrillator Data

NCT01161589

COMPLETED NA

Asthma Intervention Research 2 (AIR2) Trial

NCT00231114

COMPLETED Phase 4

ULTRA Study for Pacemaker Patients

NCT00133289

COMPLETED Phase 4

RIGHT: Rhythm ID Going Head-to-Head Trial

NCT00148954

TERMINATED Phase 3

Guidant Microwave Ablation System for the Treatment of Atrial Fibrillation

NCT00111488

COMPLETED NA

The Prevention of Myocardial Enlargement and Dilatation Post Myocardial Infarction Study

NCT00605631

COMPLETED Phase 2

EASYTRAK 4 Steerable LV Lead

NCT00158964

COMPLETED Phase 3

Direct Stenting of TAXUS Liberté™-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions

NCT00371423

← Previous Page 5 of 6 Next →

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 16
Phase 3 33
Phase 4 26

Where Boston Scientific Corporation enrollment is open (later-stage tilt)

22 recruiting of 280 indexed (8% open); 207 completed (74%).

Phase mix: 59 late (III/IV) vs 23 early (I/II) (later-stage heavy).

Top condition: Coronary Artery Disease (8 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Boston Scientific Corporation: open-pipeline peers nationwide

Peers matched on 280 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Boston Scientific Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 0%5%10%15%20%25% Total trials Recruiting share Boston Scientific CorporationRegeneron PharmaceuticalsAlcon ResearchEisaiSWOG Cancer Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Novo Nordisk A/SHoffmann-La RocheUnited Therapeutics
Boston Scientific Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Boston Scientific Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 280 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

What to do with this Boston Scientific Corporation page

280 registered trials is a research-attention snapshot, not an endorsement of Boston Scientific Corporation or any single study.

  • 22 of Boston Scientific Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Coronary Artery Disease is the condition Boston Scientific Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Coronary Artery Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Boston Scientific Corporation pipeline card: 280 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.